Background: Peanut allergy necessitates dietary restrictions, preferably individualized
| INTRODUCTION
Peanut allergy, the most common cause of severe and fatal allergic reactions in children in the western world, 1 has increased in prevalence over the last two decades 2, 3 currently affecting 1%-2%
of the paediatric population. 4 Once established, peanut allergy is likely to last a lifetime. 5, 6 The only established therapy is peanut avoidance and rescue medication, including intramuscular epinephrine auto injectors in case of severe systemic reactions. Nevertheless, accidental exposures frequently occur due to poorly labelled foods, manufacturing errors and peanut contamination. 7 Consequently, quality of life is reduced in peanut-allergic children and their families. [8] [9] [10] Diagnosing peanut allergy requires a convincing history of allergic reaction related to peanut exposure, supported by clinical and immunological investigations and/or an oral food challenge (OFC) to peanut. Clinical investigations include skin prick tests (SPT) and possibly the recently reported clinical conjunctival allergen provocation test (CAPT), 11 whereas immunological investigations include specific Immunoglobulin E (s-IgE) to peanut and its allergen components as well as the basophil activation test (BAT). [12] [13] [14] Clinical reactions to peanut have been associated with weal size of SPT and s-IgE levels to peanut, 15, 16 while s-IgE to the peanut component allergen Ara h 2 has been shown to be the best predictor of allergic reactions [17] [18] [19] with levels exceeding 1.00 kUA/L conferring a 97% probability of a systemic reaction. 20 Allergy reaction severity has been associated with basophil activation, 21 and with peanut SPT and s-IgE in some 13, 22, 23 but not all 24, 25 studies, whereas the ratio of s-IgG 4 /s-IgE to peanut 26 and peanut s-IgE/total IgE 27 has been associated with diagnostic outcome of OFC. Finally, reactivity threshold has been associated with peanut SPT and s-IgE to peanut, Ara h 2 and basophil activation. 23, 24 Reactivity threshold is necessary to personalize precautions related to peanut exposure, preferably determined by a doubleblinded placebo-controlled food challenge (DBPCFC) and reported as the cumulated amount of peanut intake at the time of a positive OFC 28 or as the lowest amount of peanut protein that elicited mild, objective symptoms, that is the lowest observed adverse effect level (LOAEL). 28 However, children with the greatest likelihood of severe and life-threatening reactions are often excluded from DBPCFC and oral immunotherapy (OIT) due to the risk of systemic reactions. 29 Screening children with peanut allergy for enrolment in the open randomised controlled (RCT) peanut OIT trial; "Take-Away food allergy; inducing tolerance in children allergic to peanut" (the TakeAway trial), included clinical and immunological investigations as well a DBPCFC to determine reactivity threshold and severity grade of allergic reaction.
The primary aim of this study was to determine whether clinical and/or immunological characteristics were associated with reactivity threshold in children with anaphylaxis to peanut, and secondarily to investigate whether these characteristics were associated with severity of the allergic reaction.
2 | METHODS
| Study design
This study setting was a 3-day investigation programme for children screened for eligibility for enrolment into the ongoing Take-Away 
| Study population
This study included 96 children with a positive DBPCFC. Of the 213 children referred for screening, 113 did not wish to enter the study, did not fulfil the inclusion and exclusion criteria or withdrew during screening and 4 had a negative DBPCFC (Figure 1 ).
| Methods
A structured parental interview including history of allergic reactions, allergic comorbidities and medical history of the child, use of medication and sociodemographic data was performed on day one.
Lung function was measured by maximal expiratory flow volume loops in accordance with international standards, 30 and reported by percentage predicted forced expiratory volume in one-second (FEV 1 %) using the reference values of Zapletal.
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Skin prick tests were performed using peanut and 11 other common food and inhalant allergens (see online supplement) according to international guidelines. | 417
Anaphylaxis was defined as moderate symptoms from at least two organ systems in line with European Academy of Allergy and Clinical Immunology (EAACI) task force position papers 41, 42 ( Table S2) , modified for children by Vetander et al. 43 Severity of anaphylaxis was also graded in line with the EAACI position papers 41, 42 scoring from 1 to 3 (mild-moderate-severe) in addition to the method of Sampson (Grading of Food-Induced Anaphylaxis According to Severity of Clinical Symptoms) ranging from one to five (extremely severe reaction). 44 
| Outcomes and predictors
The primary outcome was reactivity threshold, defined as the cumulated peanut protein (mg) intake at positive DBPCFC. The LOAEL 28 was used as an additional threshold value and set to 3 mg for children with a positive DBPCFC at the first challenge dose.
Very low reactivity threshold was defined as a DBPCFC reactivity threshold of ≤3 mg of peanut protein.
The secondary outcome was severity of the allergic reaction during DBPCFC.
Potential predictors were baseline characteristics (age and gen- 
| Statistical analyses
Due to non-normal distribution, continuous baseline characteristics are presented by geometric mean (95% CI) and median (range), and categorical data are presented as number of cases (n) with percentage (%). Furthermore, bivariate unadjusted analyses were performed with Spearman correlation analyses (r s = Spearman correlation coefficient In multiple robust regression analyses, reactivity threshold was significantly associated with basophil activation, peanut SPT, Ara h 2 and the ratios of peanut s-IgE/total IgE and s-IgG 4 /s-IgE to peanut (Table 2) . Neither peanut CAPT nor s-IgE or SPT t to peanut was significantly associated with reactivity threshold. Repeating the analyses for LOAEL, significant association was found with peanut SPT, s-IgE to peanut, the ratio of peanut s-IgE/total IgE and basophil activation, but not with Ara h 2, the ratio s-IgG 4 /s-IgE to peanut, peanut SPT t and peanut CAPT ( Table 2 ).
Subgroup analyses after excluding 23 children with a basophil activation ≤15% CD63 + (non-responders [n = 6] and the low responders [n = 17]) from the model gave similar results for reactivity threshold and for LOAEL (data not shown).
Basophil activation was significantly associated with immunological and clinical test results with closest association with peanut CAPT (b = À7.60, P = .02) ( Table 3 ) and with age among girls (r s = .31, P = .04), but not among boys (r s = À.009, P = .95). Additionally, basophil activation was the best predictor of very low reactivity threshold (<3 mg of peanut protein) (Figure 2) , with an optimal cut-off of 75.8% giving a 93.5% negative predictive value (Table S1 ).
Neither peanut SPT or SPT t nor CAPT to peanut nor any of the immunological parameters was significantly associated with severity of allergic reaction in the Hosmer step down multivariate robust regression analysis (data not shown).
T A B L E 1 Baseline characteristics from screening in the Take-Away trial n (%) Geometric mean (95% CI) Median (min, max) between CD-sens and % CD63 + (r s = .60, P = <.01) 21 and a 100% concordance has been shown between CD-sens and a positive DBPCFC. 34 In the present study, basophil activation expressed as % CD63 + best predicted very low threshold level (<3 mg of peanut SPT, skin prick test; Ig, immunoglobulin; BAT, basophil activation given as percentage-activated CD63 cells test; -, no significant association. Associations are given as the relative change (ß) related to each mg increase in peanut threshold. N = 86, BAT was not performed in 10 children due to missed sampling (n = 5) or technical causes (n = 5). SPT, skin prick test; Ig, immunoglobulin; BAT, basophil activation test, CAPT, conjunctival allergen provocation test. The coefficient represents the relative change related to percentage increase in activated basophils. N = 80, BAT was not performed in 10 children due to missed sampling (n = 5) or technical causes (n = 5), non-responders are excluded (n = 6).
a Dilution steps at which the test was considered positive.
F I G U R E 2 Receiver operating characteristic curves predicting very low threshold (<3 mg of peanut protein). The basophil activation test used 5 ng/mL of allergen protein), whereas CD-sens could not be assessed due to strong basophil activation even at the lowest concentration of 2.5 ng/mL allergen extract, reflecting a study population with very low reactivity threshold.
Our finding of significant associations between reactivity threshold and peanut SPT and Ara h 2 is in line with previous reports in children 21, 24 and young adults. 23 In addition to correlation with basophil activation, Blumchen et al 24 ing the lowest cumulated dose at which a mild objective symptom was noted. Additionally, the discrepancies may be due to the estimated rather than measured LOAEL in our study, with the first challenge dose of 3 mg. The estimated LOAEL may also explain why basophil activation was less strongly correlated to LOAEL than reactivity threshold and why the correlation is weak (r s = À.02). On the other side, such a low correlation may also be irrelevant. It has been suggested that ideally, the highest dose that does not elicit objective symptoms (NOAEL = no observed adverse effect level) should be determined for defining the exact LOAEL, 35 but this was not possible in our study. The post hoc decision to also determine LOAEL was made to facilitate comparisons across studies with different stopping criteria of OFC. 35, 36, 40 Some studies use only subjective symptoms that occur in consecutive doses as a sign of a positive OFC, 17, 46 although subjective symptoms may occur at doses 20-fold lower than the LOAEL 47 and some patients report no subjective symptoms prior to the objective symptoms. 24 Determining LOAEL might also be helpful in identifying the peanut exposure amount that elicited the first symptom or sign related to the importance of food labelling. 28 The severity of allergic reactions was not associated with any of the clinical or immunological characteristics in the present study, in line with the study of Blumchen et al, 24 but in contrast to the MIRA-BEL study, 48 in which baseline characteristics like age (teenagers and adults), asthma and not having atopic dermatitis were associated with more severe allergic reactions. Also, peanut SPT, 13 24 although they suggested that their modified food challenge would result in a lower LOAEL.
Also, the DBPCFC was stopped when it was defined positive, which may have prohibited more severe reactions. Basophil activation on the other hand can be regarded as an "in vitro challenge" 12 that can proceed to higher doses. In the present study, it was associated with immunological and clinical test results shown to predict severity grade of allergic reaction, 13, [21] [22] [23] which may suggest a relationship between allergy severity and reactivity. This finding is in line with the previously reported association between severity of allergic reaction and reactivity threshold (P = .027). 51 To our knowledge, the association between basophil activation in the present study with the peanut CAPT dilution at which subjects experienced allergy symptoms and signs 11 has not been shown previously, but is supported by the study of Varney et al 52 where conjunctival provocation threshold increased significantly after specific immunotherapy to cat dander. Finally, we found basophil activation also to correlate with female gender, a finding we are not aware has been shown previously. The clinical relevance of the latter finding is not clear.
| Strengths and limitations
All 96 children had confirmed primary peanut allergy by DBPCFC, with moderate objective signs from at least two organ systems, excluding only skin symptoms and very mild symptoms as anaphylaxis 41, 42 in line with international standards, and the study included a novel CAPT to peanut to assess potential biological correlates.
However, as all children had anaphylaxis this may limit the possibility to identify correlations across a wider variation of reactivity thresholds and severity reactions. Although we found immunological and clinical test results to correlate to reactivity thresholds and LOAEL within our study population, the generalizability of our study may be limited to children with similar peanut allergy severity. Further, to be REIER-NILSEN ET AL.
| 421 able to address biomarkers associated with very low reactivity threshold and LOAEL, the study would have benefited from setting a lower starting dose than was chosen for the study. Finally, a potential limitation to interpretation of the results may be that thresholds determined by OFC are not completely reproducible.
53,54

| CONCLUSION
In children with anaphylaxis to peanut, basophil activation, peanut SPT and the ratio of peanut s-IgE/total IgE were associated with reactivity threshold and LOAEL. None of the clinical or immunological markers appeared sufficient to substitute oral peanut challenge to determine reactivity threshold, and none were associated with severity of the allergic reactions.
